"Apple's Solution to Import Ban: Removing Blood-Oxygen Functionality from Apple Watch Series 9"

The U.S. Customs agency has ruled that Apple's proposed redesign of the Apple Watch Series 9 and Ultra 2 does not infringe on Masimo patents, as long as the devices no longer contain pulse oximetry features. This decision allows Apple to continue selling the watches in the U.S. without the blood oxygen functionality. However, the outcome of Apple's request to pause the Apple Watch ban during the appeals process is still pending, with a decision expected soon from the US appeals court.